Technical Analysis for CLDX - Celldex Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 10.29 1.58% 0.16
CLDX closed down 5.24 percent on Tuesday, August 11, 2020, on 17 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Down
Historical CLDX trend table...

Date Alert Name Type % Chg
Fell Below 50 DMA Bearish 1.58%
New Downtrend Bearish 1.58%
Down 3 Days in a Row Weakness 1.58%
20 DMA Resistance Bearish -3.74%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.74%
Inside Day Range Contraction -3.74%
Fell Below 20 DMA Bearish -7.63%
Doji - Bearish? Reversal -7.63%
Outside Day Range Expansion -7.63%
20 DMA Support Bullish -12.13%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused precision targeted immunotherapy platform. Its lead drug candidates include rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma and a Phase II study for the treatment of recurrent glioblastoma; and CDX-011, an antibody-drug conjugate, which completed a randomized Phase IIb study for the treatment of advanced breast cancer. The company also has various earlier stage candidates in clinical development, such as CDX-1135, a molecule that inhibits a part of the immune system called the complement system; CDX-1127, a therapeutic fully human monoclonal antibody for cancer indications that is in Phase I study in patients with selected malignant solid tumors or hematologic cancers; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor, which completed Phase I study in healthy subjects; and CDX-1401, an antibody-targeted technology program for cancer indications that completed Phase I study in combination with toll-like receptor agonists poly-ICLC. Its preclinical product candidate includes CDX-014, a human monoclonal antibody-drug conjugate that targets TIM-1, a molecule that is expressed on renal and ovarian cancers with minimal expression in normal tissues. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Thomas Jefferson University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.
Medicine Biotechnology Biopharmaceutical Cancer Clinical Medicine Immunology Treatment Of Cancer Immunotherapy Immune System Cancer Treatments Monoclonal Antibodies Antibody Drug Conjugates Seattle Genetics Cancer Research Amgen Hematologic Cancers Advanced Breast Cancer Recurrent Glioblastoma Rockefeller University Targeted Immunotherapy Treatment Of Advanced Breast Cancer

Is CLDX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 13.91
52 Week Low 1.5
Average Volume 3,434,408
200-Day Moving Average 4.30
50-Day Moving Average 10.30
20-Day Moving Average 11.16
10-Day Moving Average 10.79
Average True Range 1.06
ADX 25.78
+DI 18.84
-DI 20.12
Chandelier Exit (Long, 3 ATRs ) 10.32
Chandelier Exit (Short, 3 ATRs ) 12.76
Upper Bollinger Band 12.54
Lower Bollinger Band 9.79
Percent B (%b) 0.12
BandWidth 24.66
MACD Line 0.07
MACD Signal Line 0.25
MACD Histogram -0.1796
Fundamentals Value
Market Cap 1.3 Billion
Num Shares 128 Million
EPS -1.09
Price-to-Earnings (P/E) Ratio -9.29
Price-to-Sales 32.43
Price-to-Book 1.32
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.45
Resistance 3 (R3) 11.56 11.22 11.23
Resistance 2 (R2) 11.22 10.89 11.17 11.16
Resistance 1 (R1) 10.68 10.68 10.51 10.57 11.08
Pivot Point 10.34 10.34 10.26 10.29 10.34
Support 1 (S1) 9.80 10.01 9.63 9.69 9.18
Support 2 (S2) 9.46 9.80 9.41 9.10
Support 3 (S3) 8.92 9.46 9.03
Support 4 (S4) 8.81